Today, we’re delighted to welcome Alison Finger, MBA, the Chief Operating Officer at Vicero Bio—a preclinical-stage biotech company pioneering VINCOBODY therapies, a next-generation nanobody platform being developed to tackle immune-mediated diseases and cancer. Since stepping into the COO role in September 2023, Alison has been at the helm of Vicero’s business operations, steering strategic and financial planning, company build-out, and business development initiatives.Prior to Vicero, Alison spent several years as Chief Commercial Officer at bluebird bio, where she led global strategy and commercialization for transformative gene and cell therapy products. Earlier in her career, she held multiple leadership roles at Bristol-Myers Squibb—including Managing Director for Australia/New Zealand and global franchise leadership in oncology, neurology, and virology—where she guided portfolio development and global launches across geographies.Join us in this episode at we talk through details on the pipeline, the lead programme and how the Series A raise is coming along, being in commercial roles for the bulk of her career and how the transition to more of an operating role is.
